Professional resource for practitioners · Not patient information
A practical overview of recognition and acute management of vascular events during injection of hyaluronic acid fillers, adapted for clinics in Norway, Sweden, Denmark and Finland.
Important: This is a general professional overview based on published literature, and does not replace training, the clinic's own written protocol or the assessment of the medisinsk fagansvarlig. In the event of visual changes or neurological symptoms: call the emergency number immediately. Norway 113 · Sweden, Denmark, Finland 112.
| Timing | Clinical signs |
| Immediately (during/right after injection) | Marked blanching (white, blood-drained skin), pain clearly disproportionately severe relative to the injection, mottled livedo-like pattern |
| Minutes to hours | Persistent blanching that does not normalise, dusky (blue-violet) discolouration, delayed capillary refill |
| Hours to 1–2 days | Progressive discolouration, blister formation, increasing pain, signs of incipient tissue necrosis |
| At any time — acute emergency | Visual changes, eye pain, reduced eye movement, headache with neurological deficits → suspect ophthalmic or cerebral embolisation |
Published protocols for the «flooding» technique describe perilesional injection of high-dose hyaluronidase — reported in the literature in the order of 500 to 4500 IU — infiltrated through and around the ischaemic area, repeated every 30 to 60 minutes until sustained reperfusion is achieved. More recent studies have also examined ultrasound-guided injection of lower, more precise doses directly into the affected vessel, with promising results and fewer adverse effects.
Note: These doses are taken from published peer-reviewed literature and are considerably higher than doses used for elective dissolution of filler. A genuine vascular emergency requires the clinic to have a sufficient quantity of hyaluronidase available — not just a single ampoule intended for correcting aesthetic results.
For calcium hydroxylapatite- and poly-L-lactic acid-based products there is no enzymatic reversal agent. Management is mainly supportive — warmth, massage and early specialist contact — and underlines why prevention and aspiration before injection is especially important with these products.
Fillers are medical devices, and serious incidents are subject to mandatory reporting. Each Nordic country has its own supervisory authority:
| Country | Responsible authority |
| Norway | DMP — Direktoratet for medisinske produkter |
| Sweden | Läkemedelsverket |
| Denmark | Lægemiddelstyrelsen |
| Finland | Fimea |
The classic early signs are immediate blanching (white, blood-drained skin) in the injection area, pain that is disproportionately severe compared with the injection itself, and a livedo-like, mottled skin pattern. Later, dusky (blue-violet) discolouration, delayed capillary refill and ultimately blisters or tissue necrosis may develop if the occlusion is not treated.
Stop the injection immediately. Assess the area clinically. In confirmed or strongly suspected occlusion from hyaluronic acid filler, high-dose hyaluronidase perilesionally («flooding» technique) is first-line treatment in accordance with current literature, combined with warm compresses and massage. The clinic should follow the protocol of its own medisinsk fagansvarlig, and hyaluronidase should always be available before any filler treatment.
Visual changes, eye pain or reduced movement of the eye after injection is an immediate medical emergency requiring immediate hospital admission and ophthalmological assessment. Call the emergency number at once (113 in Norway, 112 in Sweden, Denmark and Finland) while local high-dose hyaluronidase is initiated pending transport, in accordance with structured protocols for filler-induced vision loss.
No. Hyaluronidase breaks down hyaluronic acid and is therefore only effective against hyaluronic acid-based fillers. For calcium hydroxylapatite (Radiesse) and poly-L-lactic acid (Sculptra) there is no equivalent reversal agent, and the management of vascular events with these products is more limited to supportive treatment and early specialist contact.
Serious incidents involving medical devices such as hyaluronic acid fillers must be reported to the national medicines/medical device authority: DMP (Direktoratet for medisinske produkter) in Norway, Läkemedelsverket in Sweden, Lægemiddelstyrelsen in Denmark, and Fimea in Finland. The reporting obligation applies regardless of whether the complication was managed successfully or not.
Filler complications are a growing source of complaints and compensation claims. A clinic should have a written SOP for vascular events, hyaluronidase available in sufficient quantity for a genuine emergency (not only for elective dissolution), as well as routines for consent, photographs and record-keeping that document both prevention and response.
A vascular event is managed in minutes, not hours. The clinic should have a written SOP, a sufficient quantity of injectable hyaluronidase in stock for a genuine emergency, and routines for documentation and reporting to the supervisory authority. BC Nordic is happy to assist with professional questions about preparedness.
Contact us →